These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 10817522)

  • 21. Endothelial survival factors as targets for antineoplastic therapy.
    Reinmuth N; Stoeltzing O; Liu W; Ahmad SA; Jung YD; Fan F; Parikh A; Ellis LM
    Cancer J; 2001; 7 Suppl 3():S109-19. PubMed ID: 11779081
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Angiogenesis and antiangiogenic cancer therapy].
    Pour L; Hájek R; Buchler T; Maisnar V; Smolej L
    Vnitr Lek; 2004 Dec; 50(12):930-8. PubMed ID: 15717808
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Colorectal cancer and antiangiogenic therapy: what can be expected in clinical practice?
    Mancuso A; Sternberg CN
    Crit Rev Oncol Hematol; 2005 Jul; 55(1):67-81. PubMed ID: 15890525
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor angiogenesis--a potential target in cancer chemoprevention.
    Bhat TA; Singh RP
    Food Chem Toxicol; 2008 Apr; 46(4):1334-45. PubMed ID: 17919802
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Determination of angiogenesis in human neoplasms: current prognostic and therapeutic implications.
    Fontanini G; Del Mastro L; Bevilacqua G
    Forum (Genova); 1998; 8(2):128-42. PubMed ID: 9666050
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Development of antiangiogenic chemotherapy regimens].
    Takahashi H; Kondo T
    Nihon Geka Gakkai Zasshi; 2002 Feb; 103(2):237-43. PubMed ID: 11904987
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Value of angiogenesis inhibitors in tumor diseases--preclinical data]].
    Berdel WE; Panse J
    Onkologie; 2005 Oct; 28 Suppl 4():25-8. PubMed ID: 16205102
    [No Abstract]   [Full Text] [Related]  

  • 28. Dynamical model for assessment of anti-angiogenic therapy of cancer.
    Mukherjee A; Majumder D
    Mol Biosyst; 2010 Jun; 6(6):1047-55. PubMed ID: 20358121
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma.
    Ahir BK; Engelhard HH; Lakka SS
    Mol Neurobiol; 2020 May; 57(5):2461-2478. PubMed ID: 32152825
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Addressing tumor blood vessels.
    Folkman J
    Nat Biotechnol; 1997 Jun; 15(6):510. PubMed ID: 9181567
    [No Abstract]   [Full Text] [Related]  

  • 31. Molecular targets in the inhibition of angiogenesis.
    Dudek AZ; Pawlak WZ; Kirstein MN
    Expert Opin Ther Targets; 2003 Aug; 7(4):527-41. PubMed ID: 12885272
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endothelial vascular toxicity from chemotherapeutic agents: preclinical evidence and clinical implications.
    Soultati A; Mountzios G; Avgerinou C; Papaxoinis G; Pectasides D; Dimopoulos MA; Papadimitriou C
    Cancer Treat Rev; 2012 Aug; 38(5):473-83. PubMed ID: 21982720
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Angiogenesis as a therapeutic target in cancer.
    Kumaran G; Clamp AR; Jayson GC
    Clin Med (Lond); 2008 Aug; 8(4):455-8. PubMed ID: 18724620
    [No Abstract]   [Full Text] [Related]  

  • 34. Antiangiogenic cancer drug using the zebrafish model.
    Santoro MM
    Arterioscler Thromb Vasc Biol; 2014 Sep; 34(9):1846-53. PubMed ID: 24903092
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phenotypic profiling identifies novel anticancer drugs.
    Cancer Discov; 2011 Dec; 1(7):OF1. PubMed ID: 22586692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A review on pro- and anti-angiogenic factors as targets of clinical intervention.
    Bouïs D; Kusumanto Y; Meijer C; Mulder NH; Hospers GA
    Pharmacol Res; 2006 Feb; 53(2):89-103. PubMed ID: 16321545
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor angiogenesis--new drugs on the block.
    Brower V
    Nat Biotechnol; 1999 Oct; 17(10):963-8. PubMed ID: 10504695
    [No Abstract]   [Full Text] [Related]  

  • 38. An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action.
    Gradishar WJ
    Invest New Drugs; 1997; 15(1):49-59. PubMed ID: 9195289
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disruption of matrix metalloproteinase 2 binding to integrin alpha vbeta 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo.
    Silletti S; Kessler T; Goldberg J; Boger DL; Cheresh DA
    Proc Natl Acad Sci U S A; 2001 Jan; 98(1):119-24. PubMed ID: 11134507
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanisms and future directions for angiogenesis-based cancer therapies.
    Scappaticci FA
    J Clin Oncol; 2002 Sep; 20(18):3906-27. PubMed ID: 12228212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.